Showing results (201-210 of 432) with videos related to
Sort By:
Pageof 44
The Journal of Antimicrobial Chemotherapy|September 4, 2016
Effectiveness and safety of an abacavir/lamivudine + rilpivirine regimen for the treatment of HIV-1 infection in naive patientsAdrian Curran, Jhon Rojas, Alfonso Cabello, et al.AIDS Research and Human Retroviruses|December 21, 2010
Impact of switching from lopinavir/ritonavir to atazanavir/ritonavir on body fat redistribution in virologically suppressed HIV-infected adultsElena Ferrer, Luis del Rio, Esteban Martínez, et al.The Journal of Antimicrobial Chemotherapy|December 20, 2014
Reduced darunavir dose is as effective in maintaining HIV suppression as the standard dose in virologically suppressed HIV-infected patients: a randomized clinical trialJosé Moltó, Marta Valle, Elena Ferrer, et al.Diagnostics (Basel, Switzerland)|November 27, 2021
Growth Differentiation Factor 15 (GDF-15): A Novel Biomarker Associated with Poorer Respiratory Function in COVID-19Leticia Alserawan, Patricia Peñacoba, Sandra Elizabet Orozco Echevarría, et al.AIDS (London, England)|July 12, 2012
Trends in mortality according to hepatitis C virus serostatus in the era of combination antiretroviral therapyJuan Berenguer, Belén Alejos, Victoria Hernando, et al.Alcohol (Fayetteville, N.Y.)|June 24, 2010
Polymorphisms in the interleukin-10 gene promoter and the risk of alcoholism and alcoholic liver disease in Caucasian Spaniard menTeresa Auguet, Francesc Vidal, Montserrat Broch, et al.Journal of Acquired Immune Deficiency Syndromes (1999)|October 17, 2014
Shorter telomere length predicts poorer immunological recovery in virologically suppressed HIV-1-infected patients treated with combined antiretroviral therapyJosé-Ramón Blanco, Inma Jarrin, Alfredo Martinez, et al.Clinical Pharmacokinetics|January 5, 2007
Lopinavir/ritonavir pharmacokinetics in HIV and hepatitis C virus co-infected patients without liver function impairment: influence of liver fibrosisJosé Moltó, Marta Valle, Asunción Blanco, et al.AIDS (London, England)|September 29, 2012
Changes in cardiovascular biomarkers in HIV-infected patients switching from ritonavir-boosted protease inhibitors to raltegravirEsteban Martínez, Polyana M D'Albuquerque, Josep M Llibre, et al.AIDS (London, England)|January 27, 2007
Three-year follow-up of protease inhibitor-based regimen simplification in HIV-infected patientsEsteban Martínez, Juan A Arnaiz, Daniel Podzamczer, et al.Pageof 44